New subsidiary will further the Company’s research into treating COVID-related heart muscle injury. A patent has been filed for a therapy to ameliorate and potentially repair myocardial damage. NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Healthtech Solutions, Inc. (OTC: HLTT) (the “Company”), parent company of Medi-Scan, Inc., today […]
Coronary/Structural Heart
Elixir Medical Announces Commencement of INFINITY-SWEDEHEART Randomized Controlled Trial of DynamX Coronary Bioadaptor System
2,400-Patient Trial Utilizes Globally-Respected SWEDEHEART Registry Database in Randomized Study of First Metallic Device Treating Coronary Artery Disease That Adapts to Vessel Physiology MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced commencement of the INFINITY-SWEDEHEART randomized controlled trial (RCT) of the DynamX™ Coronary Bioadaptor System, the […]
Zora Biosciences Licenses Ceramide Technology to Quest Diagnostics for Cardiovascular Mortality Prediction Test
SECAUCUS, N.J. and HELSINKI, March 15, 2021 /PRNewswire/ — Zora Biosciences Oy, a clinical diagnostics company whose mission is to identify robust markers of disease and develop them into high-throughput, health-economic value-added clinical methods, today announced it has signed a non-exclusive license agreement with Quest Diagnostics (NYSE: DGX), the world leader in diagnostic information services, […]
Altasciences Conducts Preclinical Studies in Support of Verve Therapeutics’ Gene Editing Approach for Cardiovascular Disease
LAVAL, Quebec–(BUSINESS WIRE)–Altasciences is proud to have conducted preclinical studies for Verve Therapeutics that support the development and advancement of Verve’s gene editing approach to treating cardiovascular diseases. Altasciences’ Seattle team performed intravenous preclinical studies, including supporting analyses of pharmacodynamic markers and whole liver DNA editing, in non-human primates, that show […]
Eko Launches Eko Academy to Help Medical Students and Healthcare Providers Strengthen their Stethoscope Skills and Auscultation Knowledge
New educational app from the leading cardiopulmonary digital health company offers clinical screening resources and real world application on identifying heart and lung abnormalities OAKLAND, Calif., March 11, 2021 (GLOBE NEWSWIRE) — Eko, a cardiopulmonary digital health company, today announced the launch of its clinical education initiative. Eko Academy, a free […]
Longeveron’s Lomecel-B™ Approved by FDA for Compassionate Use for the Treatment of Child with Hypoplastic Left Heart Syndrome (HLHS)
MIAMI, March 11, 2021 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the U.S. Food & Drug Administration (FDA) has granted expanded access approval for the administration of Longeveron’s investigational cell […]
Gore REDUCE Clinical Study Five-Year Results Demonstrate That PFO Closure With The GORE® CARDIOFORM Septal Occluder Provides Safe Long-Term Reduction Of Recurrent Stroke
– Published in the New England Journal of Medicine (NEJM), the REDUCE Study continues to show the largest reduction in recurrent ischemic stroke in all PFO shunt sizes over medical therapy alone.*,¹ – Long-term results highlight GORE® CARDIOFORM Septal Occluder can be trusted for patient safety and effective defect closure. FLAGSTAFF, Ariz., March […]
Lipigon Expands Collaboration With HitGen by Selecting Second Target
CHENGDU, China–(BUSINESS WIRE)–Lipigon Pharmaceuticals AB (”Lipigon”), developer of therapeutics for lipid-related diseases, today announced that the company has expanded its agreement with the Shanghai STAR listed company HitGen Inc. (”HitGen”) to include a second novel target. With joint efforts, the aim is to develop a treatment for cardiometabolic disease. Lipigon […]
Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCE-FMR trial
Muhammad Shahzeb Khan, Tariq Jamal Siddiqi, Javed Butler, Tim Friede, Wayne C. Levy, Klaus K. Witte, Janusz Lipiecki, Horst Sievert, Andrew J. Stewart Coats First published: 22 February 2021 https://doi.org/10.1002/ehf2.13273 Abstract Aims The objective of this study was to compare functional outcomes through 1 year in patients with core‐lab verified moderate […]
MedAlliance Receives Fourth FDA Breakthrough Device Designation for Sirolimus Drug-Eluting Balloon in Treatment of De Novo Coronary Lesions
NYON, Switzerland, March 4, 2021 /PRNewswire/ — MedAlliance, the first drug-eluting balloon (DEB) company in the world to receive US Food and Drug Administration (FDA) Breakthrough Device Designation Status for a sirolimus DEB, has now been awarded breakthrough status for SELUTION SLR™, its sustained limus release DEB catheter, in the treatment of atherosclerotic lesions […]
